A nurse is preparing to witness informed consent for a client having surgery. Which of the following priority information should the nurse share with the client while witnessing consent?

A. Simvastatin: This HMG-CoA reductase inhibitor is used for lipid management and does not interact with iodinated contrast media to cause renal injury. There is no pharmacological contraindication for continuing statin therapy before a radiological study. Withholding this medication is unnecessary and does not provide protective benefits for the kidneys.

B. Pantoprazole: As a proton pump inhibitor, this medication manages gastric acid secretion and has no known synergistic toxicity with IV contrast dyes. It does not influence the hemodynamic or excretory functions of the renal system. Continuation of pantoprazole does not increase the risk of contrast-induced nephropathy or metabolic complications.

C. Valsartan: This angiotensin II receptor blocker is used for blood pressure control and is not typically withheld specifically for contrast studies unless acute kidney injury is already present. While it affects renal perfusion, it does not carry the same metabolic risk as other diabetic medications. Standard protocol allows for the administration of this drug pre-procedure.

D. Metformin: This medication must be withheld prior to and for 48 hours after contrast administration due to the risk of lactic acidosis. Contrast dye can cause transient renal impairment, leading to the accumulation of metformin in the bloodstream. Excessive metformin levels trigger a dangerous shift in systemic pH, resulting in metabolic acidosis.

A. Assisting with early ambulation: Early ambulation involves helping the client walk shortly after surgery to prevent venous thromboembolism and promote gastrointestinal motility. While moving can stimulate bladder activity, documenting a specific voiding event is a direct assessment of renal and bladder output. This action focuses on mobility rather than the physiological excretion of urine.

B. Managing postoperative pain: Pain management involves assessing comfort levels and administering analgesics or non-pharmacological interventions to facilitate recovery. Monitoring for the first void after catheter removal is a safety measure to detect urinary retention rather than an analgesic intervention. Successful voiding indicates the absence of anesthesia-induced bladder atony or urethral trauma.

C. Monitoring urinary function: Removing an indwelling catheter necessitates close observation to ensure the client regains the ability to void spontaneously and effectively. Documenting the timing and volume of the first void confirms that the detrusor muscle and urethral sphincter are functioning correctly post-anesthesia. This is a critical component of assessing renal and urological recovery.

D. Providing surgical site or wound care: Wound care focuses on inspecting incisions for signs of infection, dehiscence, or hematoma and performing sterile dressing changes. Urinary output is an internal physiological process and does not directly relate to the integrity of cutaneous surgical margins. Tracking micturition is a functional assessment rather than a local tissue intervention.